Henk-Jan Boiten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Henk-Jan Boiten has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
Roelf Valkema
Department of Nuclear Medicine, Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands
5 shared publicationsRon T. van Domburg
Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Thoraxcenter Room Ba304, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
5 shared publicationsArend F. L. Schinkel
Department of Cardiology, Thoraxcenter, Erasmus Medical Center, Thoraxcenter Room Ba304, 's-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
4 shared publicationsFelix Zijlstra
Department of Cardiology, Erasmus Medical Center, Rotterdam, The Netherlands
4 shared publicationsEduard J. Libourel
Department of Internal Medicine - Hematology, Franciscus Gasthuis and Vlietland, Schiedam, The Netherlands
2 shared publicationsHuib Ceelie
Department of Clinical Chemistry, Franciscus Gasthuis and Vlietland, Schiedam, The Netherlands
2 shared publications
Latest Publications
- 21 October 2025
- Published by Wiley in Hematological Oncology
- Vol. 43 (6) , e70147
Thioguanine Therapy in Essential Thrombocytosis and Polycythemia Vera
- 21 October 2025
- Published by Wiley in Hematological Oncology
- Vol. 43 (6) , e70147
Thioguanine Therapy in Essential Thrombocytosis and Polycythemia Vera
- 2 September 2025
- Published by Taylor & Francis in Immunotherapy
- Vol. 17 (13) , 913-916
Multifocal sclerotic lesions in Erdheim–Chester disease successfully treated with tocilizumab
A 58-year-old woman presented to the outpatient clinic with invalidating bone pain in the proximal lower extremities. Laboratory testing showed increased inflammation parameters with a normocytic anemia. Bone scintigraphy revealed increased uptake in both radii, distal femurs, tibiae, and fibulae. PET/CT scanning showed irregular sclerotic bone lesions without other abnormalities. Multiple bone biopsies showed histiocytes expressing CD68 and Factor XIIIa. Metastatic or hematopoietic neoplasms were ruled out. A diagnosis of Erdheim-Chester disease (ECD) with solely osseous involvement was made. Treatment with tocilizumab weekly, an IL-6 receptor antibody, was successful. Tocilizumab appears to be a promising agent for the treatment of patients with Erdheim-Chester disease with limited organ involvement.
- 2 September 2025
- Published by Taylor & Francis in Immunotherapy
- Vol. 17 (13) , 913-916
Multifocal sclerotic lesions in Erdheim–Chester disease successfully treated with tocilizumab
A 58-year-old woman presented to the outpatient clinic with invalidating bone pain in the proximal lower extremities. Laboratory testing showed increased inflammation parameters with a normocytic anemia. Bone scintigraphy revealed increased uptake in both radii, distal femurs, tibiae, and fibulae. PET/CT scanning showed irregular sclerotic bone lesions without other abnormalities. Multiple bone biopsies showed histiocytes expressing CD68 and Factor XIIIa. Metastatic or hematopoietic neoplasms were ruled out. A diagnosis of Erdheim-Chester disease (ECD) with solely osseous involvement was made. Treatment with tocilizumab weekly, an IL-6 receptor antibody, was successful. Tocilizumab appears to be a promising agent for the treatment of patients with Erdheim-Chester disease with limited organ involvement.
- 23 August 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (8) , e70577
Successful Treatment With Tocilizumab for Refractory RS‐Virus‐Induced Hemophagocytic Lymphohistiocytosis in Multiple Myeloma
Hemophagocytic lymphohistiocytosis (HLH) may be triggered by infections (mostly viral infections). HLH triggered by the evolving respiratory syncytial virus (RSV) is rare. HLH is characterized by excessive immune activation and is life‐threatening with high mortality. We show that tocilizumab led to a rapid clinical improvement in a multirefractory RSV‐induced HLH patient. Tocilizumab appears to be a promising therapeutic option and is well‐tolerated.
- 23 August 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (8) , e70577
Successful Treatment With Tocilizumab for Refractory RS‐Virus‐Induced Hemophagocytic Lymphohistiocytosis in Multiple Myeloma
Hemophagocytic lymphohistiocytosis (HLH) may be triggered by infections (mostly viral infections). HLH triggered by the evolving respiratory syncytial virus (RSV) is rare. HLH is characterized by excessive immune activation and is life‐threatening with high mortality. We show that tocilizumab led to a rapid clinical improvement in a multirefractory RSV‐induced HLH patient. Tocilizumab appears to be a promising therapeutic option and is well‐tolerated.
- 15 August 2025
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 7 (1) , 1-3
Polycythemia and normal erythropoietin level: still clear cell renal cell carcinoma
- 15 August 2025
- Published by Springer Nature in SN Comprehensive Clinical Medicine
- Vol. 7 (1) , 1-3
Polycythemia and normal erythropoietin level: still clear cell renal cell carcinoma
- 19 June 2024
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 43 (8) , 1677-1678
Plasmacytosis without plasma cell disorder: beware of Dengue
- 19 June 2024
- Published by Springer Nature in European Journal of Clinical Microbiology & Infectious Diseases
- Vol. 43 (8) , 1677-1678
Plasmacytosis without plasma cell disorder: beware of Dengue
- 14 February 2023
- Published by Wiley in British Journal of Haematology
- Vol. 201 (2) , 179
The value of bone marrow aspiration during analysis of fever, pancytopenia and splenomegaly: Diagnosing visceral leishmaniasis
- 14 February 2023
- Published by Wiley in British Journal of Haematology
- Vol. 201 (2) , 179
The value of bone marrow aspiration during analysis of fever, pancytopenia and splenomegaly: Diagnosing visceral leishmaniasis
- 26 November 2021
- Published by Springer Nature in Annals of Hematology
- Vol. 101 (6) , 1359-1360
Fever of unknown origin during treatment of mantle-cell lymphoma: is it relapsing disease?
- 26 November 2021
- Published by Springer Nature in Annals of Hematology
- Vol. 101 (6) , 1359-1360
Fever of unknown origin during treatment of mantle-cell lymphoma: is it relapsing disease?
- 2 August 2021
- Published by Springer Nature in Annals of Hematology
- Vol. 100 (11) , 2871-2872
An abdominal mass with thrombosis due to inferior vena cava agenesis mimicking lymphoma
- 2 August 2021
- Published by Springer Nature in Annals of Hematology
- Vol. 100 (11) , 2871-2872
An abdominal mass with thrombosis due to inferior vena cava agenesis mimicking lymphoma
- Open Access
- 1 May 2021
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 106, 262-264
Multi-organ failure with necrotic skin lesions due to infection with Chlamydia psittaci
- 1 May 2021
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 106, 262-264
Open AccessMulti-organ failure with necrotic skin lesions due to infection with Chlamydia psittaci
- 18 February 2021
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (9) , 3619-3621
Adalimumab‐induced platelet antibodies resulting in severe thrombocytopenia
Anti‐tumor necrosis factor alpha (TNFα) agents are effective in diseases including Crohn’s disease (CD) but may cause cytopenias. The mechanisms involved in anti‐TNFα agents induced thrombocytopenia are scarce. We report a 73‐year‐old male with Crohn's disease for which he currently used adalimumab, an anti‐TNFα agent. He had received mesalazine and infliximab before the treatment of adalimumab. No comorbidities were present. Routine laboratory tests revealed a deep thrombocytopenia (thrombocytes 24x10*9/L) after which adalimumab was discontinued. Bleeding symptoms included cutaneous hematomas and mild epistaxis. Direct monoclonal antibody‐specific immobilization of platelet antigens (MAIPA assay) revealed autoantibodies specific to glycoprotein IIb/IIIa (GPIIb/IIIa) and glycoprotein V (GPV) platelet receptors. There was no bone marrow suppression. Other causes of the thrombocytopenia were ruled out. The platelet count normalized after adalimumab discontinuation. No further interventions were required. Monitoring thrombocyte levels after initiating anti‐TNFα agents is recommended, which could lead to prevention of this potential fatal phenomenon.
- 18 February 2021
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (9) , 3619-3621
Adalimumab‐induced platelet antibodies resulting in severe thrombocytopenia
Anti‐tumor necrosis factor alpha (TNFα) agents are effective in diseases including Crohn’s disease (CD) but may cause cytopenias. The mechanisms involved in anti‐TNFα agents induced thrombocytopenia are scarce. We report a 73‐year‐old male with Crohn's disease for which he currently used adalimumab, an anti‐TNFα agent. He had received mesalazine and infliximab before the treatment of adalimumab. No comorbidities were present. Routine laboratory tests revealed a deep thrombocytopenia (thrombocytes 24x10*9/L) after which adalimumab was discontinued. Bleeding symptoms included cutaneous hematomas and mild epistaxis. Direct monoclonal antibody‐specific immobilization of platelet antigens (MAIPA assay) revealed autoantibodies specific to glycoprotein IIb/IIIa (GPIIb/IIIa) and glycoprotein V (GPV) platelet receptors. There was no bone marrow suppression. Other causes of the thrombocytopenia were ruled out. The platelet count normalized after adalimumab discontinuation. No further interventions were required. Monitoring thrombocyte levels after initiating anti‐TNFα agents is recommended, which could lead to prevention of this potential fatal phenomenon.